German-born cancer biologist Hans-Guido Wendel is taking advantage of transformative advances in genomics technology to understand key genetic abnormalities in leukemia and lymphoma.
Originally explored as a cancer drug, the tree-derived chemical is now being mined for its antiviral properties.
In the Lab
New research from Sloan Kettering Institute investigators pinpoints altered cell metabolism as a cause of B cell lymphoma.
Finding
The discovery suggests a potential new treatment approach for certain cancers.
In the Lab
The reason certain patients with follicular lymphoma do worse than others may come down to a missing gene.
In the Lab
A new immunotherapy approach involves engineering CAR T cells to produce proteins that treat lymphoma.
In the Lab
Researchers have engineered a gene into therapeutic cells that allows them to turn off tumor growth if some of the cells become cancerous.
In the Lab
Memorial Sloan Kettering researchers have found a naturally occurring compound that can destroy cancer cells in mice by targeting <em>MYC</em>, a cancer-causing gene that has remained elusive until now.
Cancer biologists Mark Ptashne, Robert Benezra, and Hans-Guido Wendel commented on the promise and challenges of new treatments for cancer....
Profile
German-born cancer biologist Hans-Guido Wendel is taking advantage of transformative advances in genomics technology to understand key genetic abnormalities in leukemia and lymphoma.
Memorial Sloan Kettering has announced the creation of the Louis V. Gerstner, Jr. Young Investigators Fund and has named the fund's first four recipients.
